格隆汇9月15日｜港股市场脑机接口概念股脑动极光-B(6681.HK)拉升大涨超80%，报13.78港元，为连续 第三日上涨，股价创上市新高，截至目前成交额放大至7亿港元。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

格隆汇9月15日｜港股市场脑机接口概念股脑动极光-B(6681.HK)拉升大涨超80%，报13.78港元，为连续 第三日上涨，股价创上市新高，截至目前成交额放大至7亿港元。 ...

Core Viewpoint - Brainstorming Aurora-B (06681) experienced a significant stock price increase, reaching a new high since its listing, following its inclusion in the Hong Kong Stock Connect program [1] Group 1: Stock Performance - The stock surged over 83% in early trading, peaking at 13.78 HKD, marking a cumulative increase of 1.3 times since its market entry [1] - As of the report, the stock was up 61.73%, trading at 12.13 HKD with a transaction volume of 1.054 billion HKD [1] Group 2: Company Developments - Starting from September 8, Brainstorming Aurora was officially included in the Hong Kong Stock Connect list [1] - The company is recognized as the first in China to develop medical-grade digital therapy products targeting cognitive disorders, with its core product being the first to receive regulatory approval in this category (registered in September 2018) [1] - On September 12, the company announced via its official WeChat account that its series of products received the Beijing New Technology, New Product, and New Service Certificate [1] Group 3: Product Features - The products focus on intelligent assessment and precise intervention, boasting several advantages: reliance on large sample norms for accurate evaluation, multi-modal refined assessment to enhance intervention effectiveness, and an intelligent digital diagnosis and treatment platform that overcomes situational limitations [1]

Core Viewpoint - Brain动极光-B (06681) has seen a significant stock price increase, rising over 83% to a new high of 13.78 HKD since its listing, with a cumulative increase of 1.3 times since its debut [1] Group 1: Stock Performance - As of the latest update, the stock price has increased by 61.73%, trading at 12.13 HKD with a transaction volume of 1.054 billion HKD [1] - The stock was officially included in the Hong Kong Stock Connect list starting September 8 [1] Group 2: Company Overview - Brain动极光 is the first domestic company to develop medical-grade digital therapy products targeting cognitive disorders [1] - Its core product is the first cognitive disorder digital therapy product in China to receive regulatory approval, obtaining its first registration certificate in September 2018 [1] Group 3: Product Features - The company's products have recently received the Beijing New Technology, New Product, and New Service Certificate [1] - The products focus on intelligent assessment and precise intervention, featuring advantages such as precise evaluation based on large sample norms, multi-modal refined assessment to enhance intervention effectiveness, and an intelligent digital diagnosis and treatment platform that overcomes situational limitations [1]

9月12日，脑动极光(06681.HK)涨超50%，高见9.47港元创上市新高。截至发稿，涨50.44%，报8.52港 元，成交额5.79亿港元。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Brainstorm Aurora (06681), which rose over 50% to reach a new high of 9.47 HKD following its inclusion in the Hong Kong Stock Connect program effective September 8, 2025 [1] - As of the report, the stock was trading at 8.52 HKD with a trading volume of 579 million HKD, reflecting strong market interest [1] - The company reported a revenue of 100 million HKD for the first half of 2025, representing a year-on-year increase of 92.82% [1] Group 2 - The company has made significant advancements in its core pipeline in research and clinical trials, achieving commercialization for eight indications across four major types of cognitive disorders [1] - Additionally, the company is actively developing treatments for other cognitive disorder indications [1] - The company is pushing for innovation and application of AI in the medical field, having developed a proprietary medical large model, BrainAuGPT, which received a national invention patent for its novel training task combination method based on GBR second-order knowledge representation [1]

智通财经APP获悉，脑动极光(06681)涨超50%，高见9.47港元创上市新高。截至发稿，涨50.44%，报 8.52港元，成交额5.79亿港元。 消息面上，沪深交易所发布公告，调整港股通标的证券名单，其中，脑动极光获纳入港股通，2025年9 月8日起生效。公司此前发布的2025年中期业绩显示，期内集团取得收入1亿元，同比增加92.82% 公司指出，今年上半年核心管线在科研及临床试验方面取得重大进展，核心产品已就四种主要类型认知 障碍的八种适应症实现商业化，并正就其他几种认知障碍适应症进行开发。另外，公司还不断推动AI 在医疗领域的创新和应用，自主研发的医疗大模型BrainAuGPT，首次提出的基于GBR二阶知识表达的 大语言模型的训练任务组合推荐方法获得国家发明专利授权。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 更改於開曼群島的註冊辦事處地址 腦動極光醫療科技有限公司（「本公司」）董事會（「董事會」）宣佈，本公司於開 曼群島的註冊辦事處的地址已更改，自2025年6月1日起，至#4-210, Governors Sq., 23 Lime Tree Bay Avenue, PO Box 32311, Grand Cayman KY1-1209, Cayman Islands。 承董事會命 腦動極光醫療科技有限公司 譚錚先生 主席兼執行董事 香港，2025年9月11日 截至本公告日期，董事會包括：(i)執行董事譚錚先生；(ii)非執行董事李思睿先 生、李明秋女士及Deng Feng先生；及(iii)獨立非執行董事林曉波先生、段濤博士 及李月中先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | | 增加 / 減少 (-) | | 0 | | | USD | | 0 | | 本月底結存 | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].